Information Center
Xinkanghe has completed the administration of the first subject in the clinical trial of the world's first IL-25 monoclonal antibody.
Release time:
2022-06-17 10:05
On June 17, 2022, XinKangHe Biopharmaceutical Technology Co., Ltd. ("XinKangHe") successfully enrolled the first subject for the global first trial of its independently developed new target project XKH001 (First in Human).
XKH001 is the first IL-25 targeted antibody drug (First-in-Class) developed independently by the XinKangHe team, which has received clinical trial approval in both China and the United States. IL-25 uniquely acts on the upstream of the Th2 cell signaling pathway, and is expressed in the submucosa of the bronchial tissue in the central nervous system and asthma patients, which can regulate allergic reactions and type 2 immune diseases. By blocking the binding of IL-25 to its receptor, XKH001 will inhibit and reduce the inflammatory response of downstream pathways, providing more and better treatment options for inflammatory and autoimmune diseases such as asthma, with significant clinical value and market potential.
The Phase I clinical trial of this project is being conducted at the First Hospital of Jilin University, with Director Ding Yanhua serving as the principal investigator (PI) of the Phase I clinical trial ward. The Phase I clinical trial aims to evaluate the safety, tolerability, and pharmacokinetics of XKH001 in healthy subjects through a randomized, double-blind, placebo-controlled study, providing scientific data for decision-making in future clinical research involving patients.
Since its establishment, XinKangHe Biopharmaceutical has focused on the research and development of innovative antibody drugs, continuously enriching its R&D pipeline and enhancing its R&D capabilities. Mr. Wang Yaning, the company's CEO, stated: "The global first innovative drug targeting IL25, XKH001, has officially entered Phase I clinical trials, which not only marks a good beginning for XinKangHe's independently innovative product line but will also accumulate valuable clinical trial experience for other globally innovative products independently developed by the company, marking a milestone for XinKangHe's independent innovation and R&D!"
In the future, XinKangHe will continue to focus on autoimmune diseases and immuno-oncology, building a first-class domestic and world-leading professional antibody R&D and transformation platform, accelerating the development and clinical research of global innovative antibody drugs.
Global, research and development, innovation, drugs, clinical, independent, antibodies, clinical trials
Related News
Beijing Address: A203, Zhongguancun Biomedical Park, No.5, Development Road, Haidian District, Beijing
Zhejiang Address: Floor 8, Building 7, Dongsheng Huigu, 1299 Kehai Avenue, Keqiao District, Shaoxing City, Zhejiang Province
Contact Phone:010-82176552
E-mail:hr@kanovabiopharma.com